<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01220245</url>
  </required_header>
  <id_info>
    <org_study_id>721-070910</org_study_id>
    <nct_id>NCT01220245</nct_id>
  </id_info>
  <brief_title>SuperB Trial: SUrgical Versus PERcutaneous Bypass</brief_title>
  <acronym>SuperB</acronym>
  <official_title>Heparin-bonded Endoluminal Versus Surgical Femoropopliteal Bypass; a Multicentre Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rijnstate Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this multicentre Randomized Clinical Trial, the heparin-bonded endoluminal bypass will be&#xD;
      compared to the surgical venous femoro-popliteal bypass, based on the non-inferiority&#xD;
      principle for the patency. Besides equal patency, an improved quality of life is expected.&#xD;
      Recruitment will take the first two years and patients will be followed during five years.&#xD;
      Patients with an indication for surgical bypass, classified category 3-6 with a &gt;50% stenosis&#xD;
      or occlusion of the SFA over &gt;/=10 cm in length will be included. At least one crural artery&#xD;
      should be patent without significant lesions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">August 2020</completion_date>
  <primary_completion_date type="Actual">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary (and -assisted) patency</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary patency</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-intervention</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularisation</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Heparin-bonded endoluminal fempop bypass</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heparin-bonded ePTFE endoluminal femoro-popliteal bypass versus surgical femoro-popliteal bypass</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical femoro-popliteal bypass</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgical femoro-popliteal bypass.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Heparin-bonded ePTFE endoluminal fem-pop bypass</intervention_name>
    <description>Heparin-bonded ePTFE endoluminal femoropopliteal bypass versus surgical femoropopliteal bypass</description>
    <arm_group_label>Heparin-bonded endoluminal fempop bypass</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical femoro-popliteal bypass.</intervention_name>
    <description>Surgical femoro-popliteal bypass.</description>
    <arm_group_label>Surgical femoro-popliteal bypass</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Novo stenosis, restenosis &gt;50% or occlusion of the native SFA, all &gt; 10cm in length&#xD;
&#xD;
          -  Patent popliteal artery at the upper margin of the patella to the trifurcation&#xD;
&#xD;
          -  Diameter native SFA and popliteal artery are 5.0-7.5 mm&#xD;
&#xD;
          -  Indication for surgical bypass&#xD;
&#xD;
          -  Distal run-off at least one crural artery without significant stenosis&#xD;
&#xD;
          -  Ankle-brachial index (ABI) at rest &lt; 0.8 in the study limb prior to procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient unsuitable for administration of contrast agent&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Dementia or altered mental status that would prohibit giving conscious informed&#xD;
             consent&#xD;
&#xD;
          -  Need for adjunctive major surgical or vascular procedures within one month&#xD;
&#xD;
          -  Untreated flow-limiting aortoiliac occlusive disease&#xD;
&#xD;
          -  Perioperative unsuccessful ipsilateral percutaneous vascular procedure to treat inflow&#xD;
             disease just prior to enrollment&#xD;
&#xD;
          -  Femoral or popliteal aneurysm of target vessel&#xD;
&#xD;
          -  Non-arthrotic disease resulting in occlusion (e.g. embolism, Buerger's disease,&#xD;
             vasculitis)&#xD;
&#xD;
          -  Severe medical comorbidities (untreated CAD/CHF, severe COPD, metastatic malignancies,&#xD;
             dementia etc.) or other medical condition that would preclude compliance with study&#xD;
             protocol&#xD;
&#xD;
          -  Major distal amputation (above the transmetatarsal) in the study limb&#xD;
&#xD;
          -  Any previously known coagulation disorder, including hypercoagulability&#xD;
&#xD;
          -  Contraindication to anticoagulation or antiplatelet therapy&#xD;
&#xD;
          -  Known allergies to stent/stent-graft components&#xD;
&#xD;
          -  History of prior life-threatening reaction to contrast agent&#xD;
&#xD;
          -  Patients with known hypersensitivity to heparin, including those patients who have had&#xD;
             a previous incidence of heparin-induced thrombocytopenia (HIT) type II&#xD;
&#xD;
          -  Planned surgical procedure or major amputation to occur after enrollment of the&#xD;
             patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MMJP Reijnen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rijnstate Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nij Smellinghe Hospital</name>
      <address>
        <city>Drachten</city>
        <state>Friesland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antonius Hospital</name>
      <address>
        <city>Sneek</city>
        <state>Friesland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slingeland Hospital</name>
      <address>
        <city>Doetinchem</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala klinieken</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 11, 2010</study_first_submitted>
  <study_first_submitted_qc>October 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rijnstate Hospital</investigator_affiliation>
    <investigator_full_name>Michel Reijnen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>endoluminal</keyword>
  <keyword>surgical</keyword>
  <keyword>bypass</keyword>
  <keyword>patency</keyword>
  <keyword>quality of life</keyword>
  <keyword>multicentre</keyword>
  <keyword>RCT</keyword>
  <keyword>superficial femoral artery</keyword>
  <keyword>vascular patency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

